Galapagos Archives -

Paul Stoffels’ retirement at the end of last year after nine years as head of R&D at Johnson

Paul Stoffels swiftly resurfaces as Galapagos’ next CEO

https://pharmaphorum.com/news/paul-stoffels-swiftly-resurfaces-as-galapagos-next-ceo/

UK green lights Gilead Sciences, Galapagos ulcerative colitis drug

Joy Persaud Galapagos, Gilead, market access, MHRA, pharma 0 Comment

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Jyseleca (filgotinib) 200mg tablets to treat ulcerative

UK green lights Gilead Sciences, Galapagos ulcerative colitis drug

https://pharmaphorum.com/news/uk-green-lights-gilead-sciences-galapagos-ulcerative-colitis-drug/

News/ News/ Sales and Marketing

Galapagos’ long-serving CEO Onno van de Stolpe to retire

Phil Taylor Galapagos, Gilead Sciences, senior management 0 Comment

After 22 years at the helm of Belgian biotech Galapagos, chief executive Onno van de Stolpe has decided

Galapagos’ long-serving CEO Onno van de Stolpe to retire

https://pharmaphorum.com/news/galapagos-long-serving-ceo-onno-van-de-stolpe-to-retire/

News/ News/ R&D

Trials leave Galapagos’ SIK programme looking under the weather

Phil Taylor Galapagos, Gilead Sciences, psoriasis, Rheumatoid arthritis, SIK inhibitor, ulcerative colitis 0 Comment

Galapagos has had to send its SIK inhibitor programme back to the drawing board after its lead compound

Trials leave Galapagos’ SIK programme looking under the weather

https://pharmaphorum.com/news/trials-leave-galapagos-sik-programme-looking-under-the-weather/

Market Access/ Podcast/ Video/ Views & Analysis/ Views and analysis

Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaphorum podcast

mike.smith@pharmaphorum.com Galapagos, HTA, Michael Smyth, podcast, rna 0 Comment

Episode 35 of the pharmaphorum podcast hears from Michael Smyth about Galapagos UK and joining the company as

Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaphorum podcast

https://pharmaphorum.com/market-access-2/podcast-galapagos-uk-michael-smyth-rna/

News/ News/ R&D

Gilead/Galapagos alliance hit again as IPF drug is binned

Phil Taylor fibrosis, Galapagos, Gilead Sciences, idiopathic pulmonary fibrosis, partnership, respiratory disease 0 Comment

Gilead and Galapagos’ much-trumpeted R&D alliance has suffered another setback with the abandonment of ziritaxestat after a late-stage

Gilead/Galapagos alliance hit again as IPF drug is binned

https://pharmaphorum.com/news/gilead-galapagos-alliance-hit-again-as-ipf-drug-is-binned/

Market Access/ News/ News

NICE backs broad use for Gilead/Galapagos arthritis pill Jyseleca

Phil Taylor filgotinib, Galapagos, Gilead, HEOR, NHS, NICE, Rheumatoid arthritis 0 Comment

Patients with rheumatoid arthritis (RA) in England will be able to get treatment with Gilead Sciences and Galapagos’

NICE backs broad use for Gilead/Galapagos arthritis pill Jyseleca

https://pharmaphorum.com/news/nice-backs-broad-use-for-gilead-galapagos-arthritis-pill-jyseleca/

News/ News/ Sales and Marketing

Gilead’s rheumatoid arthritis pill approved in Japan

Richard Staines Eisai, filgotinib, Galapagos, Gilead, Jyseleca, Rheumatoid arthritis 0 Comment

Gilead has scored a major approval for its troubled rheumatoid arthritis pill filgotinib, after regulators in Japan granted

Gilead’s rheumatoid arthritis pill approved in Japan

https://pharmaphorum.com/news/gileads-rheumatoid-arthritis-pill-approved-in-japan/

News/ News/ R&D/ Top stories

Analysts question Gilead’s commitment to arthritis drug after FDA setback

Richard Staines Galapagos, Gilead, inflammatory diseases, Rheumatoid arthritis, ulcerative colitis 0 Comment

The FDA has rejected Gilead and Galapagos’ rheumatoid arthritis (RA) pill filgotinib over concerns that it could damage

Analysts question Gilead’s commitment to arthritis drug after FDA setback

https://pharmaphorum.com/news/gilead-could-become/

Trending

Galapagos

Login